AKRX Stock Recent News Akorn Inc (AKRX) 38.21 11/14/2014 17:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Akorn Inc (AKRX) 38.21 $AKRX

SmarTrend Watching for Potential Pullback in Shares of Akorn After 1.41% Gain
Comtex SmarTrend(R) - 41 mins ago
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $36.90 to a high of $38.51. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $37.85 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 38.21 (+0.53)

Synageva Up on New Phase III Data on Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 56 mins ago
Synageva BioPharma Corp. (GEVA) announced the presentation of new data from a phase III study on sebelipase alfa for LAL deficiency.
GEVA: 75.26 (-1.84), AKRX: 38.21 (+0.53), ADHD: 3.66 (+0.06), CELG: 104.05 (-3.38)

Akorn (AKRX) Worth Watching: Stock Adds 6.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 7:51AM CST
Akorn, Inc. (AKRX) was a big mover last session, as its shares rose over 6% on the day.
MNK: 88.11 (+1.15), KBIO: 2.10 (+0.04), AKRX: 38.21 (+0.53), MYL: 54.05 (-0.68)

Upgrade Alert for Akorn (AKRX)
Comtex SmarTrend(R) - Fri Nov 14, 7:03AM CST
Akorn (NASDAQ:AKRX) was upgraded from Fair Value to Buy at CRT Capital today. The stock closed yesterday at $37.68 on volume of 3.0 million shares, above average daily volume of 1.7 million. Akorn (NASDAQ:AKRX) has potential upside of 9.0% based on a current price of $37.68 and analysts' consensus price target of $41.08. Akorn shares should encounter resistance at the 50-day moving average (MA) of $38.00 and support at its 200-day MA of $30.77.
AKRX: 38.21 (+0.53)

Stocks Rally Back After Midday Sell-Off
at Investor's Business Daily - Thu Nov 13, 12:17PM CST
Stocks were trying to recover after a midday sell-off lopped off most of the morning gains. The Nasdaq rose 0.3%, the S&P 500 was flat and the Dow Jones industrial average was up 0.2%. Volume was running at a higher pace than at the same time...
DDS: 111.79 (-0.97), AKRX: 38.21 (+0.53), WMT: 82.96 (+0.02), THRM: 40.43 (+0.30)

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ICUI: 85.71 (+0.76), AKRX: 38.21 (+0.53), WPC: 66.05 (-0.60), FLWS: 8.98 (-0.03), MMSI: 14.96 (-0.08)

Stocks Open With Mild Losses; American Eagle, Macys Jump
at Investor's Business Daily - Wed Nov 12, 9:35AM CST
Stocks opened to mild losses in mixed trade Wednesday, as company earnings reports fueled much of the early action. The Dow Jones industrial average and the S&P 500 each dipped 0.2%. The Nasdaq shed a bit less than 0.1%. The stock market today got...
AMBA: 47.84 (+0.10), AKRX: 38.21 (+0.53), AEO: 13.50 (-0.08), M: 62.05 (+0.48), FANG: 67.79 (+3.03)

Look for Shares of Akorn to Potentially Rebound after Yesterday's 1.18% Sell Off
Comtex SmarTrend(R) - Mon Nov 10, 5:02PM CST
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $35.02 to a high of $36.36. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $35.04 on volume of 2.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AKRX: 38.21 (+0.53)

Akorn (AKRX) Downgraded From Buy to Hold
at The Street - Mon Nov 10, 8:19AM CST
Akorn (AKRX) has been downgraded by TheStreet Ratings from Buy to Hold with a ratings score of C+.
AKRX: 38.21 (+0.53)

Health Sell-Offs Drag On IBD 50
at Investor's Business Daily - Fri Nov 07, 6:31PM CST
The IBD 50 was lower last week as several stocks in health care sold off, dragging down the index's performance. After two weeks of feverish gains, the IBD 50 components cooled off the first week of November. The index was down 1.4% last week,...
BCC: 37.03 (-0.16), LCI: 46.88 (-1.40), AKRX: 38.21 (+0.53), AFSI: 52.48 (+0.32), EXPE: 87.93 (+1.44), FFIV: 128.88 (+2.73), SLXP: 102.32 (+5.33), MPWR: 45.46 (+0.59), TMH: 54.48 (+0.57), ATHM: 44.58 (+1.59)

Stocks In Retreat After Jobs Report; Monster Beverage Gains
at Investor's Business Daily - Fri Nov 07, 9:31AM CST
jobs report, Arista Networks earnings, leading stocks, Monster Beverage stock, breakout stocks Stocks opened lower Friday after disappointing gains in October payrolls. The Nasdaq slumped 0.4% due to weakness in networking, biotech and solar issues....
MNST: 107.92 (-0.24), ANET: 77.69 (+0.72), AKRX: 38.21 (+0.53), ATHM: 44.58 (+1.59)

A/D Rating Helps Spot What The Pros Are Buying
at Investor's Business Daily - Thu Nov 06, 5:41PM CST
If you're prepping a small patch of land, a shovel and a hoe from Home Depot (HD) will suffice. But if you have acres to dig up, then you'll need industrial-size earth-moving equipment. In the stock market, it takes big money from professional...
BCC: 37.03 (-0.16), HD: 98.24 (-0.76), AKRX: 38.21 (+0.53), ILMN: 180.50 (-4.50)

SmarTrend Watching for Potential Rebound in Shares of Akorn After 9.12% Loss
Comtex SmarTrend(R) - Thu Nov 06, 4:05PM CST
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $36.35 to a high of $42.49. Yesterday, the shares fell 9.1%, which took the trading range below the 3-day low of $41.17 on volume of 6.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AKRX: 38.21 (+0.53)

Stocks Gain On Draghi Comments, Economic Data
at Investor's Business Daily - Thu Nov 06, 3:25PM CST
Stocks scored modest gains Thursday, thanks in part to ECB President Mario Draghi's pledge for stimulus and better-than-expected domestic data on jobless claims and productivity. The Dow Jones industrial average and the S&P 500 rose 0.4% each. Both...
GPRO: 79.15 (+2.68), SWIR: 38.31 (-0.65), AAP: 144.81 (-1.19), AKRX: 38.21 (+0.53), BABA: 115.10 (+0.26)

Akorn's (AKRX) CEO Rajat Rai on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 3:17PM CST

AKRX: 38.21 (+0.53)

Akorn (AKRX) Stock Lower Today After Reporting Third Quarter Earnings Results
at The Street - Thu Nov 06, 2:50PM CST
Shares of Akorn (AKRX) are down after reporting 2014 third quarter earnings that revealed $39.9 million in costs related to price increases.
AKRX: 38.21 (+0.53)

Stocks Up Slightly After Choppy Action
at Investor's Business Daily - Thu Nov 06, 12:26PM CST
Stocks were modestly higher after struggling for direction earlier. Overall, equities have wavered Thursday amid news of potential stimulus by the European Central Bank and better-than-expected data on jobless claims and productivity. The Dow Jones...
GPRO: 79.15 (+2.68), SWIR: 38.31 (-0.65), AKRX: 38.21 (+0.53), FRGI: 56.98 (+0.55), BABA: 115.10 (+0.26)

Akorn drops after earnings report
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 12:20PM CST

AKRX: 38.21 (+0.53)

Video: Akorn Reports 'Messy' Quarter, Slamming Stock
at Investor's Business Daily - Thu Nov 06, 12:19PM CST
Generic-drug maker and IBD 50 stock Akorn (AKRX) on Thursday reported Q3 results complicated by accounting issues, sending the stock down nearly 11% in afternoon trade on the stock market today . The company's revenue totaled $132.7 million, up 62%...
AKRX: 38.21 (+0.53)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 3

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 3

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 3

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Your Rights as a Humacyte, Inc. Investor

Updated Category News Views 110

Understanding Your Rights as a Humacyte, Inc. Investor Humacyte, Inc. (NASDAQ: HUMA) has recently captured the attention of investors due to certain legal developments affecting its share value. If you are a shareholder who purchased shares during the specific class period of May 10, 2024, to October 17, 2024, you may want to take active steps to protect your investment...

Continue Reading
Jim Chanos Raises Concerns About Oracle's Accounting Issues

Updated Category News Views 552

Chanos Questions Oracle's Accounting Practices Notable short-seller Jim Chanos has recently highlighted some serious concerns regarding Oracle Corp's accounting integrity. He has voiced skepticism about the company's massive project backlog, especially a significant $300 billion deal partnered with OpenAI, emphasizing that its operational realization is years away and...

Continue Reading
Cyrus Biotechnology Advances Novel IgG Therapy with No Antibodies

Updated Category News Views 171

Promising Developments by Cyrus Biotechnology Cyrus Biotechnology, Inc. has unveiled groundbreaking data showcasing the effectiveness of its engineered IgG-degrading enzyme, CYR241, in a unique rabbit redosing model. This enzyme demonstrates significant therapeutic activity without the formation of anti-drug antibodies (ADAs) upon repeated administration. Understanding...

Continue Reading
GreenPower Motor Company: Strengthening Its Financial Future

Updated Category News Views 241

GreenPower Motor Company Secures New Term Loan Funding GreenPower Motor Company Inc. (NASDAQ: GP), an innovator in the production and distribution of all-electric medium and heavy-duty vehicles, recently completed the closing of the fifth tranche of its secured term loan offering. This strategic move aims to bolster its operational capabilities, particularly in the cargo,...

Continue Reading
Unlocking the Future: Insights into the Cloud Industry 2025

Updated Category News Views 226

The Promising Future of the Global Cloud Industry The global cloud industry is on a fast track to remarkable growth. Recent research indicates that the market is poised to expand from approximately USD 1,091.4 billion in one year to an impressive USD 1,256.8 billion by 2025. This represents a noteworthy year-over-year increase of about 15.1%. With such staggering figures,...

Continue Reading